PPARG and fatty liver disease: Whereas increased PPARγ activity within hepatocytes would be expected to contribute to steatosis [54,55], the treatment of patients with the PPARγ agonists rosiglitazone or pioglitazone result in reduced hepatic steatosis [56,57,58].